Research is ongoing to better understand TNBC and develop more effective treatments. Recent advances include the study of PARP inhibitors for patients with BRCA mutations and the exploration of immune checkpoint inhibitors in clinical trials. These advancements hold promise for improving the management and outcomes of TNBC.
